



a
Serum BUN Levels (mg/mL)
60
50
40
30
20
10
0
Sham Surgery
Ischemia (17 mins)
p<0.01
Vehicle
RTA 402
Vehicle
RTA 402
b
Arbitrary Injury Units
6
5
4
3
2
1
0
Outer Medulla
Cortex
p<0.05
p<0.05
Vehicle
RTA 402
Vehicle
RTA 402
c
Inflammation (leukocytes/ hpf)
120
100
80
60
40
20
0
p<0.05
Vehicle
RTA 402
d
Vehicle
RTA 402


FIGS. 1a-d


a
Creatinine (mg/dl)
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Vehicle
RTA 402
Day -1
Day 1
Day 3
Day 5
p=0.018
p<0.01
b
BUN (mg/dl)
160
140
120
100
80
60
40
20
0
Vehicle
RTA 402
Day -1
Day 1
Day 3
Day 5
p<0.01
c
Vehicle
RTA 402

FIGS. 2a-c


a
Dose
(mg/m²/day)
300 900 1800
% Reduction
p ≤ 0.02
p = 0.0002
b
Dose
(mg/m²/day)
Male Dogs
0 50 150 250
Female Dogs
0 50 150 250
% Change from Baseline
c
Dose
(mg/m²/day)
Male Rats
30 60 120
Female Rats
30 60 120
% Reduction
p ≤ 0.002 for all groups
d
Dose
(mg/m²/day)
Male Rats
3 9 27
Female Rats
3 9 27
% Reduction

FIGS. 3a-d


A
All Patients
Patients with Baseline ≥1.5
Day 8
Day 15
Day 21
% Reduction from Baseline
0
-5
-10
-15
-20
-25
-30
B
All Patients
Patients with Baseline ≥1.5
Day 8
Day 15
Day 21
% Improvement from Baseline
0
5
10
15
20
25
30
35
40

FIGS. 4A-B




FIG. 5



Analysis Group ITT ≥7.0 ≥7.6
Mean Baseline 7.57 8.40 8.63
n 53 33 28
0.0
-0.2
-0.4
-0.6
-0.8
A1c (%) Change
p=0.0005
p<0.0001
p<0.0001
ITT includes patients with normal A1c
All available data included

FIG. 6



Baseline A1c ≥7.0%
Group
Mean BL
n
All
7.56%
56
All
8.36%
35
25mg
8.35%
13
75mg
8.14%
10
150mg
8.56%
12
Stage 4[1]
8.46%
11
Mean A1c (%) Change
0.00
-0.20
-0.40
-0.60
-0.80
-1.00
***
***
†
***
†
†
**
†p<0.05; **p<0.001; ***p<0.0001; [1]75mg and 150mg dose levels

FIG. 7



Group
n
All
32
Elevated
19
iNOS+
28
0%
-10%
-20%
-30%
-40%
-50%
-60%
Mean Change
†p<0.05

FIG. 8





Mean eGFR Change
40%
30%
20%
10%
0%
***
**
***
***
***
Group
BL (ml/min/m²)
n
All
34.8
57
25mg
34.8
20
75mg
32.4
18
150mg
37.1
19
Stage 4[1]
28.4
17
**p<0.001; ***p<0.0001; [1]75mg and 150mg dose levels


FIG. 9


Mean Adiponectin Change
0%
-10%
-20%
-30%
-40%
-50%
Group
n
All
34
25mg
11
75mg
13
150mg
10
***
†
**
**
†p<0.05; **p<0.001; ***p<0.0001
A
Δng ll Mean Change
0%
-10%
-20%
-30%
-40%
-50%
-60%
-70%
Group
n
All
23
25mg
9
75mg
7
150mg
7
Stage 4 CKD
10
*
†
†p<0.05; *p<0.01
B

FIGS. 10A-B


Mean BUN Change
Group
BL (mg/dl)
n
All
42.3
57
BL≥40
53.0
28
0%
-5%
-10%
-15%
-20%
-25%
**
***
**p<0.001; ***p<0.0001
A
Mean Phosphorus Change
Group
BL (mg/dl)
n
All
3.9
57
BL≥4.5
4.9
12
0%
-5%
-10%
-15%
-20%
**
**
**p<0.001
B
Mean Urice Acid Change
Group
BL (mg/dl)
n
All
8.4
57
BL≥8
10.0
31
0%
-5%
-10%
-15%
-20%
***
***
***p<0.0001
C

FIGS. 11A-C



FIGS. 12A-C



Sample: RTA-402
Size: 4.4000 mg
Method: 25-250-10
Comment: 102949, 060028 unmicronized, C, 10°C/min, 2429-98-02, r1, p1
DSC
File: I:\LIMS\EP20060937\DSC\181883.dsc
Operator: kel
Run Date: 2006-07-27 13:28
Instrument: DSC Q1000 V9.0 Build 275
221.81°C
57.16 J/g
223.62°C
156.94°C(I)
Heat Flow (W/g)
Temperature (°C)
Exo Up
Universal V4.1D TA Instruments

FIG. 13



DSC
Sample: RTA-402
Size: 3.0900 mg
Method: NM2f-25l250m0.8p60
Comment: 103418, 2497-17-01, 2°C/min, C
File: \\Dsc3\DLIMSDATA\172776.DSC
Operator: kel
Run Date: 01-Aug-2006 10:21
Instrument: 2920 MDSC V2.6A
Rev Heat Flow (W/g)
Nonrev Heat Flow (W/g)
Temperature (°C)
Exo Up
Universal V4.1D TA Instruments
195.28°C
223.19°C
121.00°C
125.40°C(I)
128.70°C

FIG. 14



RTA 402 Plasma Conc. (ng/ml)
35
30
25
20
15
10
5
0
Form A
Amorphous
0
1
2
4
6
8
16
24
Time (hr)

FIG. 15